Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 11Stomach Neoplasms 6Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Gastric Adenocarcinoma 2Cholangiocarcinoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Neoplasms of Digestive Organs 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Stromal Tumors 1Fludzoparib" and Anti-angiogenic 1Colonic Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Advanced Primary Liver Cancer 1Advanced Biliary Tract Carcinoma 1Adebrelimab 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × apatinib × 1 year × Clear all
NCT06339619 2026-06-04

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
32 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06281886 2025-11-17

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
170 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡